Sutro Biopharma, Inc. (STRO) annual income statement — 10-year revenue, gross profit & net income history
Sutro Biopharma, Inc. (STRO) annual income statement — 10-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Sales/Revenue | 45.7M | 102.48M | 62.04M | 153.73M | 67.77M | 61.88M | 42.72M | 42.74M | 38.42M | 51.74M | 59.73M |
| Revenue Growth % | -56.25% | 65.18% | -59.64% | 126.84% | 9.52% | 44.84% | -0.03% | 11.24% | -25.75% | -13.38% | - |
| Cost of Goods Sold | 1.28M | 7.32M | 7.22M | 6.82M | 8.29M | 9.77M | 76.96M | 0 | 54.26M | 51.9M | 43.55M |
| COGS % of Revenue | - | 7.15% | 11.63% | 4.43% | 12.23% | 15.79% | 180.14% | - | 141.24% | 100.3% | 72.91% |
| Gross Profit | 44.42M | 95.16M | 54.83M | 146.91M | 59.48M | 52.11M | -34.24M | 42.74M | -15.84M | -156K | 16.18M |
| Gross Margin % | 97.2% | 92.85% | 88.37% | 95.57% | 87.77% | 84.21% | -80.14% | 100% | -41.24% | -0.3% | 27.09% |
| Gross Profit Growth % | - | 73.57% | -62.68% | 146.98% | 14.16% | 252.19% | -180.12% | 369.75% | -10055.77% | -100.96% | - |
| Operating Expenses | 186.04M | 200.11M | 293.28M | 236.19M | 188.43M | 150.63M | 36.82M | 98.2M | 75.64M | 71.01M | 58.37M |
| OpEx % of Revenue | - | 195.26% | 472.7% | 153.64% | 278.03% | 243.42% | 86.18% | 229.79% | 196.89% | 137.25% | 97.72% |
| Selling, General & Admin | 32.82M | 41.02M | 48.45M | 62.58M | 59.54M | 56M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| SG&A % of Revenue | - | 40.02% | 78.1% | 40.71% | 87.86% | 90.5% | 86.18% | 76.26% | 55.65% | 31.65% | 24.81% |
| Research & Development | 144.74M | 166.42M | 252.04M | 180.43M | 137.17M | 104.4M | 76.96M | 65.61M | 54.26M | 54.64M | 43.55M |
| R&D % of Revenue | - | 162.38% | 406.24% | 117.36% | 202.4% | 168.71% | 180.14% | 153.53% | 141.24% | 105.6% | 72.91% |
| Other Operating Expenses | 201K | -7.32M | -7.22M | -6.82M | -8.29M | -9.77M | -76.96M | 0 | 1.91M | -77K | 87K |
| Operating Income | -141.62M | -104.95M | -238.45M | -89.28M | -128.94M | -98.52M | -71.06M | -55.47M | -37.22M | -19.27M | 1.36M |
| Operating Margin % | -309.87% | -102.41% | -384.34% | -58.07% | -190.26% | -159.22% | -166.32% | -129.79% | -96.89% | -37.25% | 2.28% |
| Operating Income Growth % | - | 55.99% | -167.09% | 30.76% | -30.87% | -38.65% | -28.1% | -49.02% | -93.15% | -1512.9% | - |
| EBITDA | -135.55M | -97.63M | -231.24M | -82.46M | -120.66M | -93.68M | -66.76M | -50.69M | -32.68M | -14.28M | 7.03M |
| EBITDA Margin % | -296.6% | -95.26% | -372.7% | -53.64% | -178.03% | -151.39% | -156.27% | -118.61% | -85.07% | -27.6% | 11.76% |
| EBITDA Growth % | 31.39% | 57.78% | -180.41% | 31.65% | -28.79% | -40.32% | -31.7% | -55.09% | -128.85% | -303.27% | - |
| D&A (Non-Cash Add-back) | 6.06M | 7.32M | 7.22M | 6.82M | 8.29M | 4.84M | 4.3M | 4.78M | 4.54M | 4.99M | 5.66M |
| EBIT | -140.67M | -152.97M | -187.67M | -74.73M | -113.36M | -102.4M | -28.05M | -51.39M | -37.22M | -19.08M | 1.36M |
| Net Interest Income | -33.16M | -28.96M | 13.36M | -9.24M | 109K | -2.56M | -2.47M | -276K | 16K | -416K | 251K |
| Interest Income | 6.9M | 9.25M | 44.42M | 14.51M | 3.46M | 577K | 1.51M | 4.07M | 1.62M | 273K | 251K |
| Interest Expense | 40.06M | 38.21M | 31.07M | 23.75M | 3.35M | 3.14M | 3.97M | 4.35M | 1.6M | 689K | 0 |
| Other Income/Expense | -39.11M | -86.23M | 13.36M | 677K | 12.24M | -7.01M | 38.93M | -276K | 1.91M | -416K | 338K |
| Pretax Income | -180.73M | -191.18M | -225.1M | -88.6M | -116.7M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.7M |
| Pretax Margin % | -395.46% | -186.55% | -362.81% | -57.63% | -172.2% | -170.55% | -75.2% | -130.44% | -91.93% | -38.05% | 2.85% |
| Income Tax | -96K | -93K | 2.36M | 18.19M | 2.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.05% | 0.05% | -1.05% | -20.53% | -2.14% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -180.64M | -191.09M | -227.46M | -106.79M | -119.2M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.7M |
| Net Margin % | -395.25% | -186.45% | -366.62% | -69.47% | -175.89% | -170.55% | -75.2% | -130.44% | -91.93% | -38.05% | 2.85% |
| Net Income Growth % | 13.45% | 15.99% | -112.99% | 10.41% | -12.95% | -228.49% | 42.37% | -57.84% | -79.38% | -1256.76% | - |
| Net Income (Continuing) | -180.64M | -191.09M | -227.46M | -106.79M | -119.2M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.7M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.90 | -22.49 | -29.60 | -17.80 | -23.50 | -22.90 | -9.90 | -24.30 | -15.40 | -28.10 | 38.60 |
| EPS Growth % | 30.87% | 24.02% | -66.29% | 24.26% | -2.62% | -131.31% | 59.26% | -57.79% | 45.2% | -172.8% | - |
| EPS (Basic) | - | -22.49 | -29.60 | -17.80 | -23.50 | -22.90 | -9.90 | -24.30 | -15.50 | -28.10 | 38.60 |
| Diluted Shares Outstanding | 16.57M | 8.5M | 7.68M | 6.02M | 5.07M | 4.61M | 3.26M | 2.3M | 2.29M | 699.74K | 44.12K |
| Basic Shares Outstanding | 16.57M | 8.5M | 7.68M | 6.02M | 5.07M | 4.61M | 3.26M | 2.3M | 2.29M | 699.74K | 44.12K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying STRO stock.
For fiscal year 2025, Sutro Biopharma, Inc. (STRO) reported total revenue of $102.5M. This represents a 71.6% increase compared to $59.7M in 2016.
Sutro Biopharma, Inc. (STRO) reported a net loss of $191.1M for the fiscal year ending 2025.
Sutro Biopharma, Inc. (STRO) reported an operating income of $-105.0M, resulting in an operating profit margin of -102.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Sutro Biopharma, Inc. (STRO) generated $95.2M in gross profit for the year, representing a gross profit margin of 92.9%. This demonstrates the company's core pricing power and production efficiency.